Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 ...